Results 51 to 60 of about 23,326 (221)

Keratoconjunctivitis associated with atopic dermatitis treated with tocilizumab [PDF]

, 2018
La dermatitis atópica es una enfermedad cutánea inflamatoria crónica, de diagnóstico esencialmente clínico que se manifiesta en forma de prurito y brotes recurrentes de eccema de localización típica 1 .
Ferrando Piqueres, Raúl, Pitarch Bort, Gerard, Raga Jiménez, Celia, Álvarez Martín, Tamara   +3 more
core   +4 more sources

Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status [PDF]

, 2023
Background Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab's efficacy in patients from the TRAVERSE study with or without evidence of allergic asthma and type 2
Altincatal, Arman, Busse, William W, Chupp, Geoffrey L, Deniz, Yamo, Gall, Rebecca, Izuhara, Kenji, Jacob-Nara, Juby A, Pandit-Abid, Nami, Pavord, Ian D, Rabe, Klaus, Radwan, Amr, Rowe, Paul J   +11 more
core   +1 more source

Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis

Brazilian Journal of Otorhinolaryngology
Objective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma.
Seiichiro Kamimura, Keisuke Ishitani, Ryota Morozumi, Eiji Kondo, Takahiro Azuma, Go Sato, Yoshiaki Kitamura   +6 more
doaj   +1 more source

Dupilumab Effects on Innate Lymphoid Cell and Helper T Cell Populations in Patients with Atopic Dermatitis

JID Innovations, 2021
Group 2 innate lymphoid cells (ILCs) are thought to contribute to the pathogenesis of atopic dermatitis (AD). IL-4 stimulates T helper type 2 (Th2) cells and ILC2s to proliferate and produce cytokines. Dupilumab, an antibody against the IL-4 receptor, is
Yasutomo Imai, Minori Kusakabe, Makoto Nagai, Koubun Yasuda, Kiyofumi Yamanishi   +4 more
doaj   +1 more source

144 Dupilumab restores the equilibrium of keratins and desmosomal components, integral components of the skin barrier cornified envelope [PDF]

, 2023
Elena Goleva, Evgeny Berdyshev, S. Kreimer, Irina Bronova, T. Lyubchenko, S. Bafna, Inoncent Agueusop, Robert Bissonnette, Jeffrey D. Zahn, A. Zhang, Donald Y.M. Leung   +10 more
openalex   +1 more source

Rhinology future debates, an EUFOREA report [PDF]

, 2017
The first Rhinology Future Debates was held in Brussels in December 2016, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases).
Bachert, Claus, Bernal-Sprekelsen, Manuel, Bousquet, Jean, Djandji, Michel, Dorenbaum, Alejandro, Fokkens, Wytske J, Hakim-Mehr, Dorna, Hellings, Peter W, Hendry, Stuart, Hopkins, Claire, Leunig, Andreas, Mannent, Leda, Mucha, Dirk, Onerci, Metin, Pugin, Benoit, Rowe, Paul, Seys, Sven F, Stimson, Susan, Strzembosz, Agnieszka, Toppila-Salmi, Sanna   +19 more
core   +2 more sources

Dupilumab in the treatment of severe non-control broncial asthma — economic aspects

Качественная клиническая практика, 2019
Severe non-control Bronchial Asthma (BA) is a sufficient social problem with decreasing of quality of life, high index of disability and death. New biological drug — dupilumab — would improve the situation.Materials and methods.
A. S. Salasyuk, M. Yu. Frolov, I. N. Barykina   +2 more
doaj   +1 more source

Effectiveness of tacrolimus ointment on facial lesions refractory to topical corticosteroid in patients with atopic dermatitis receiving dupilumab

Journal of Cutaneous Immunology and Allergy, 2022
Dupilumab demonstrated high efficacy and tolerable safety profiles in moderate‐to‐severe atopic dermatitis (AD) patients in clinical trials; however, certain patients suffer from facial redness, while obtaining good responses on the trunk and limbs to ...
Hideaki Uchida, Masahiro Kamata, Shota Egawa, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yayoi Tada   +10 more
doaj   +1 more source

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. [PDF]

, 2019
BackgroundComparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited.
Apfelbacher, CJ, Arents, BWM, Barbarot, S, Bosma, AL, Deleuran, M, Eichenfield, LF, Flohr, C, Gerbens, LAA, International TREAT Registry Taskforce, Irvine, AD, Manca, A, Middelkamp-Hup, MA, Schmitt, J, Spuls, PI, Vermeulen, FM, Vestergaard, C, Wall, D, Weidinger, S   +17 more
core  

Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]

, 2017
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe, Brusselle, Guy, de Haard, Hans, Godar, Marie, Lambrecht, Bart   +4 more
core   +3 more sources